STOCK TITAN

Aligos Therapeutics Inc - ALGS STOCK NEWS

Welcome to our dedicated news page for Aligos Therapeutics (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aligos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aligos Therapeutics's position in the market.

Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024 in Miami, Florida. The company focuses on developing therapeutics for liver and viral diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.33%
Tags
conferences
-
Rhea-AI Summary
Aligos Therapeutics to host a virtual KOL event featuring Dr. Stephen Harrison to discuss ALG-055009 and MASH therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences clinical trial
-
Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) appoints Jordyn Tarazi as VP of Investor Relations and Corporate Communications and Nikhil Aneja as VP of Finance. The company aims to enhance its team to support upcoming clinical data releases in liver and viral diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
management
Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) presented clinical data for its CAM-E drug candidate, ALG-000184, and THR-β drug candidate, ALG-055009, at the Hep-DART 2023 meeting. ALG-000184 showed favorable safety and significant reductions in HBV markers, while ALG-055009 demonstrated favorable safety, lipid-lowering activity, and best-in-class potential for NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.77%
Tags
clinical trial
-
Rhea-AI Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS) will present at the 2023 Piper Sandler Healthcare Conference in New York on November 30, 2023, at 12:30 p.m. ET. Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will be the presenter. The webcast link and replay details are available on the Aligos investor section of the website. The management team will also participate in investor 1x1 meetings during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
conferences
-
Rhea-AI Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS): ALG-055009, a thyroid hormone receptor-beta (THR-b) drug, demonstrated favorable PK in a Phase 1 study, lowering lipid levels in hypercholesterolemic subjects. The drug is more potent and selective than existing treatments, supporting its progression into a 12-week Phase 2a study in NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.16%
Tags
clinical trial
Rhea-AI Summary
ALG-000184 Shows Promising Results in Reducing HBV Antigens and DNA Levels, Aligos Therapeutics Announces
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
none
-
Rhea-AI Summary
Aligos Therapeutics, Inc. will present six posters at the American Association for the Study of Liver Diseases’ The Liver Meeting 2023, showcasing clinical and preclinical data on their NASH and CHB programs, including Phase 2-enabling studies and liver targeted oral PD-L1 small molecule inhibitor discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
-
Rhea-AI Summary
Aligos Therapeutics, Inc. will host a virtual KOL event featuring Mark Sulkowski, MD, to review the Late Breaking results and next steps for its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB). The event will take place on November 16, 2023, at 1:30 PM ET. The Phase 1 data will also be presented at the Liver Meeting® on November 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Rhea-AI Summary
Aligos Therapeutics reported recent business progress and financial results for Q3 2023. They raised $92 million in private placement financing, received clearance for their first US IND, and secured an $8.5 million contract with the NIAID. They are well positioned to advance their clinical programs in NASH, CHB, and coronavirus protease inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
earnings
Aligos Therapeutics Inc

Nasdaq:ALGS

ALGS Rankings

ALGS Stock Data

84.86M
37.57M
21.29%
63.14%
0.42%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
South San Francisco

About ALGS

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.